Neuromersiv is a digital health startup founded in 2017 with the mission to provide innovative solutions for neurorehabilitation using immersive virtual reality. Their flagship product, Ulysses®, is a TGA & UK MHRA registered VR based upper-limb therapy system designed to aid stroke, spinal cord, and acquired brain injury survivors in regaining lost independence and quality of life. The system achieves this by employing clinically validated, task-specific training in immersive VR to maximize engagement, compliance, and functional recovery. Based in Australia, Neuromersiv secured its last investment in a Seed Round on 01 January 2021, with the investors' details remaining undisclosed. The company operates within the health care sector, focusing on leveraging cutting-edge technology to address chronic brain-related health conditions, representing a promising investment opportunity in the rapidly evolving digital health space.
